BBLG vs. POAI, NURO, INBS, DHAI, STRR, TNON, SINT, WOK, IINN, and AEMD
Should you be buying Bone Biologics stock or one of its competitors? The main competitors of Bone Biologics include Predictive Oncology (POAI), NeuroMetrix (NURO), Intelligent Bio Solutions (INBS), DIH Holding US (DHAI), Star Equity (STRR), Tenon Medical (TNON), Sintx Technologies (SINT), WORK Medical Technology Group LTD Ordinary Shares (WOK), Inspira Technologies Oxy B.H.N. (IINN), and Aethlon Medical (AEMD). These companies are all part of the "medical equipment" industry.
Bone Biologics vs.
Bone Biologics (NASDAQ:BBLG) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings.
In the previous week, Predictive Oncology had 1 more articles in the media than Bone Biologics. MarketBeat recorded 5 mentions for Predictive Oncology and 4 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.14 beat Predictive Oncology's score of -0.67 indicating that Bone Biologics is being referred to more favorably in the media.
Predictive Oncology has a consensus price target of $3.00, indicating a potential upside of 175.23%. Given Predictive Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Predictive Oncology is more favorable than Bone Biologics.
Bone Biologics has higher earnings, but lower revenue than Predictive Oncology.
34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 6.1% of Bone Biologics shares are owned by company insiders. Comparatively, 3.4% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Bone Biologics has a net margin of 0.00% compared to Predictive Oncology's net margin of -1,012.32%. Bone Biologics' return on equity of -124.71% beat Predictive Oncology's return on equity.
Bone Biologics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Predictive Oncology received 149 more outperform votes than Bone Biologics when rated by MarketBeat users.
Summary
Bone Biologics beats Predictive Oncology on 7 of the 13 factors compared between the two stocks.
Get Bone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bone Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:BBLG) was last updated on 5/22/2025 by MarketBeat.com Staff
